Cytostatic Activity of Combretastatin A-4 Derivatives in an In Vitro System.
Bull Exp Biol Med
; 174(2): 221-225, 2022 Dec.
Article
en En
| MEDLINE
| ID: mdl-36600040
ABSTRACT
Cytostatic activity of combretastatin A-4, its 11 analogues, and paclitaxel (Taxacad) was evaluated in vitro on human tumor cells A549 (lung adenocarcinoma) and PC-3 (prostate adenocarcinoma) in order to find the active and stable compound as a promising antitumor agent. 5-(4-Methoxyphenyl)-4-(3,4,5-trimethoxyphenyl)-isoxazole (compound 123124) and 3-(3,4,5-trimethoxyphenyl)-4-(4-methoxyphenyl)-isoxazole (compound 29310186) demonstrated the highest cytostatic activity (IC50≈8×10-9 Ð). The activity of two other cytotoxic compounds (2E)-1-(7-methoxy-2H-1,3-benzodioxol-5-yl)-3-(4-methoxyphenyl)prop-2-en-1-one (compound 104815) and 4-(3-amino-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-1H-pyrazole hydrochloride (compound 198732) was close to that of Taxacad IC50 65×10-9 and 80×10-9 Ð, respectively, and are also promising active components for the development of antitumor drugs.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Estilbenos
/
Citostáticos
/
Antineoplásicos
Límite:
Humans
/
Male
Idioma:
En
Año:
2022
Tipo del documento:
Article